IDEXX Laboratories (IDXX) Stock Overview
Develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IDXX Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IDEXX Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$572.20 |
| 52 Week High | US$769.98 |
| 52 Week Low | US$485.41 |
| Beta | 1.57 |
| 1 Month Change | -0.45% |
| 3 Month Change | -11.23% |
| 1 Year Change | 16.78% |
| 3 Year Change | 17.56% |
| 5 Year Change | 10.45% |
| Change since IPO | 60,430.28% |
Recent News & Updates
Narrative Update • May 01
IDXX: Cancer Diagnostics Execution And Margin Discipline Will Guide Cooler Yet Fair Outlook
The updated analyst price target for IDEXX Laboratories has been reduced by about $19, reflecting slightly higher discount assumptions, modestly different margin expectations, and a lower future P/E multiple cited across recent research from several firms. Analyst Commentary Recent Street research for IDEXX Laboratories has leaned cautious, with several bearish analysts lowering their price targets by ranges of about $25 to $100.
Narrative Update • Apr 16
IDXX: Recurring Diagnostics And Cancer Testing Will Support Future Earnings Power
Analysts have trimmed their average price target on IDEXX Laboratories by $100. This reflects a more cautious stance, even as updated assumptions for discount rate, revenue growth, profit margins and future P/E remain broadly aligned with prior expectations.Narrative Update • Apr 01
IDXX: Cancer Diagnostics Execution And Margin Resilience Will Shape Fairly Valued Outlook
For IDEXX Laboratories, the updated analyst price target has shifted from about $579 to roughly $556 as analysts adjust their models for slightly different revenue growth and P/E assumptions, while also acknowledging a modestly higher profit margin outlook. Analyst Commentary Recent research updates show a series of lower price targets for IDEXX Laboratories, with bearish analysts trimming their expectations by amounts ranging from about $20 to roughly $100.Recent updates
Narrative Update • May 01
IDXX: Cancer Diagnostics Execution And Margin Discipline Will Guide Cooler Yet Fair Outlook
The updated analyst price target for IDEXX Laboratories has been reduced by about $19, reflecting slightly higher discount assumptions, modestly different margin expectations, and a lower future P/E multiple cited across recent research from several firms. Analyst Commentary Recent Street research for IDEXX Laboratories has leaned cautious, with several bearish analysts lowering their price targets by ranges of about $25 to $100.Narrative Update • Apr 16
IDXX: Recurring Diagnostics And Cancer Testing Will Support Future Earnings Power
Analysts have trimmed their average price target on IDEXX Laboratories by $100. This reflects a more cautious stance, even as updated assumptions for discount rate, revenue growth, profit margins and future P/E remain broadly aligned with prior expectations.Narrative Update • Apr 01
IDXX: Cancer Diagnostics Execution And Margin Resilience Will Shape Fairly Valued Outlook
For IDEXX Laboratories, the updated analyst price target has shifted from about $579 to roughly $556 as analysts adjust their models for slightly different revenue growth and P/E assumptions, while also acknowledging a modestly higher profit margin outlook. Analyst Commentary Recent research updates show a series of lower price targets for IDEXX Laboratories, with bearish analysts trimming their expectations by amounts ranging from about $20 to roughly $100.Narrative Update • Mar 18
IDXX: Recurring Diagnostics And Cancer Testing Will Support Long Term Earnings Power
Narrative Update The analyst price target for IDEXX Laboratories has been reduced by a series of cuts totaling $125, with analysts pointing to updated assumptions for revenue growth, profit margins, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on IDEXX Laboratories has centered on revised price targets, with several firms updating their models to reflect new assumptions for revenue growth, profitability, and P/E.Narrative Update • Mar 04
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Future Earnings Power
Analysts have trimmed their price target on IDEXX Laboratories by $27 to $823, citing updated assumptions around discount rates, long term growth, and future P/E expectations. Analyst Commentary Recent research commentary on IDEXX Laboratories has centered on recalibrated price targets that incorporate updated assumptions for discount rates, long term growth, and future P/E expectations.
Narrative Update • Feb 18
IDXX: New Diagnostics Pipeline And Margin Outlook Will Support Future Shareholder Value
The analyst price target for IDEXX Laboratories has been trimmed by about $4.60 as analysts factor in slightly more measured revenue growth assumptions, a modestly lower future P/E multiple, and a somewhat higher expected profit margin. Analyst Commentary Recent Street research has clustered around lower price targets for IDEXX Laboratories, with cuts of about US$20 to US$50 in quick succession.Seeking Alpha • Feb 04
IDEXX: A Great Business Trapped By A Demanding Valuation
Summary IDEXX Laboratories delivered good Q4 results, but guidance below long-term target growth rates and ongoing weakness in vet visit volumes drove a selloff. Q4 revenue grew 14% with standout performance in Companion Animal Group, but gross and operating margins came in slightly below expectations. Management exceeded its own expectations for InVue placements in 2026, and further expansion of its testing menu in 2026 will contribute to growth and margin expansion. Despite exceptional profitability and international growth potential, current valuation doesn't appear to offer good fundamentals-based long-term returns, making IDXX unattractive outside pure growth portfolios. Read the full article on Seeking AlphaNarrative Update • Feb 04
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Long Term Earnings Power
Analysts have reduced their price targets on IDEXX Laboratories by $20 to $30, reflecting updated assumptions around revenue growth, profit margins, and future P/E multiples, while maintaining a broadly similar view of fair value. Analyst Commentary Bullish analysts appear to see the recent price target cuts as more of a recalibration than a shift in their overall thesis on IDEXX Laboratories.Narrative Update • Jan 20
IDXX: Rich P/E Leaves Little Room For Cancer Diagnostics Execution Missteps
Analysts have raised their fair value estimate for IDEXX Laboratories from about US$497 to about US$579, citing higher modeled revenue growth, slightly stronger profit margins, a richer future P/E, and increased confidence in the company's product pipeline and recurring diagnostics growth following recent Q3 results and guidance updates. Analyst Commentary Street research after the Q3 update centers on two themes: confidence in IDEXX Laboratories' recurring diagnostics growth and product pipeline, and questions about how much of that strength is already reflected in the share price.Narrative Update • Jan 06
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Premium Earnings Power
Analysts have lifted their price targets on IDEXX Laboratories into a US$750 to US$805 range, citing a strong Q3 print, increased 2025 guidance, and what they describe as a compelling diagnostics pipeline along with solid recurring revenue trends as key supports for higher valuations. Analyst Commentary Recent research updates around IDEXX Laboratories cluster around a similar theme, with bullish analysts pointing to a strong Q3, raised 2025 guidance, and a diagnostics portfolio they see as well positioned in current markets.Narrative Update • Dec 16
IDXX Recurring Diagnostics Strength Will Support Premium Earnings Power Ahead
Our updated fair value estimate for IDEXX Laboratories has increased to $850 from $785, as analysts highlight a stronger than expected Q3 performance, accelerating recurring diagnostic revenue growth, and a robust innovation pipeline that supports slightly higher long term growth and margin assumptions despite a modestly higher discount rate. Analyst Commentary Recent Street research reflects a broadly constructive stance on IDEXX Laboratories following its stronger than expected Q3 results and raised 2025 guidance.Narrative Update • Dec 02
IDXX: Recent Performance and Pipeline Progress Will Support Long-Term Shareholder Value
The average analyst price target for IDEXX Laboratories has been raised, reflecting a series of upward revisions. Several targets now surpass $750, as analysts cite stronger-than-expected Q3 results and a constructive outlook on growth, innovation, and recurring revenues.Narrative Update • Nov 18
IDXX: Future Revenue Acceleration Will Drive Premium Multiples and Shareholder Returns
The analyst price target for IDEXX Laboratories has increased significantly, rising by over $50 to approximately $755. Analysts cite a stronger growth outlook, durable pricing, and robust quarterly results as supporting factors for higher valuations.Narrative Update • Nov 03
IDXX: Expanding Installed Base Will Drive Accelerating Business Momentum Ahead
The consensus analyst price target for IDEXX Laboratories has increased by over $22. This reflects growing optimism fueled by expectations of accelerating recurring revenue growth, stronger visit trends, and expanding product adoption in the company's core business lines.Narrative Update • Oct 20
Advanced Diagnostics And International Expansion Will Define Future Opportunity
The analyst fair value estimate for IDEXX Laboratories was adjusted downward to $679.92 from $695.09. Analysts highlighted accelerated consumables growth and an expanding installed base, which support long-term growth potential as market conditions normalize.Analysis Article • Aug 16
Earnings Not Telling The Story For IDEXX Laboratories, Inc. (NASDAQ:IDXX) After Shares Rise 25%
NasdaqGS:IDXX 1 Year Share Price vs Fair Value Explore IDEXX Laboratories's Fair Values from the Community and select...Analysis Article • Aug 07
IDEXX Laboratories, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
NasdaqGS:IDXX 1 Year Share Price vs Fair Value Explore IDEXX Laboratories's Fair Values from the Community and select...Narrative Update • Aug 06
Advanced Diagnostics And International Expansion Will Define Future Opportunity
IDEXX Laboratories’ consensus price target has been sharply raised, reflecting strengthened revenue growth forecasts and a higher future P/E multiple, with fair value increasing from $542.55 to $657.55. What's in the News IDEXX Laboratories raised 2025 earnings guidance, increasing revenue outlook to $4,205–$4,280 million (up $90 million at midpoint) and EPS to $12.40–$12.76 (up $0.40 at midpoint), reflecting strong recurring diagnostics revenue, higher inVue Dx instrument placements, and favorable foreign exchange.Analysis Article • Jul 23
At US$532, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Let's talk about the popular IDEXX Laboratories, Inc. ( NASDAQ:IDXX ). The company's shares saw a significant share...Analysis Article • May 11
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable
IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Apr 14
IDEXX Laboratories: I Love The Business, Not The Stock Price
Summary IDEXX Laboratories is a business that is supported by strong tailwinds, has a sticky business model with predictable, recurring revenue, all supported by an innovation-led growth strategy. There are some concerns like the way management is allocating capital, the tariff risks involving China, lower ROIC, and a declining growth rate. My main concern is with the valuation, as it is hard to justify an earnings multiple in excess of 30 when the growth rate is in the low-teens. Read the full article on Seeking AlphaSeeking Alpha • Mar 12
IDEXX Laboratories: A Top Dog In The Pet Care Market
Summary The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem. In the short term, revenue growth will be driven by the recent launch of the IDEXX inVue Dx instrument, the development of the oncology market, and the cloud-based software. Given IDEXX's competitive advantages, market growth potential, and current fair valuation, I initiate coverage with a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 10
IDEXX Laboratories And Its Real Value
Summary IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years. This article focuses on the fundamentals, the real value versus the current share price, and if IDEXX Laboratories is currently worth investing in. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Summary I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. IDEXX's future growth prospects remain promising, but current stock prices do not fully account for weak end-market demands, justifying the 'Sell' rating. Read the full article on Seeking Alpha
New Narrative • Aug 19
Global Expansion And Innovative Products Propel Revenue And Margin Growth Amidst Challenges
IDEXX's international and innovative product growth, like the inVue Dx Cellular Analyzer, fuels potential revenue and market share increases globally.Seeking Alpha • Aug 12
IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Summary IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued. Read the full article on Seeking AlphaSeeking Alpha • Jun 28
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Summary IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing rapid growth and innovation in a high-growth market. Despite a lofty valuation, IDEXX's strong financials, consistent revenue growth, and long-term growth prospects justify a Buy rating. Read the full article on Seeking AlphaShareholder Returns
| IDXX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.0% | -1.5% | 3.2% |
| 1Y | 16.8% | -19.8% | 31.0% |
Return vs Industry: IDXX exceeded the US Medical Equipment industry which returned -19.8% over the past year.
Return vs Market: IDXX underperformed the US Market which returned 31% over the past year.
Price Volatility
| IDXX volatility | |
|---|---|
| IDXX Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IDXX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IDXX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 11,000 | Jay Mazelsky | www.idexx.com |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.
IDEXX Laboratories, Inc. Fundamentals Summary
| IDXX fundamental statistics | |
|---|---|
| Market cap | US$45.69b |
| Earnings (TTM) | US$1.10b |
| Revenue (TTM) | US$4.45b |
41.2x
P/E Ratio10.2x
P/S RatioIs IDXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDXX income statement (TTM) | |
|---|---|
| Revenue | US$4.45b |
| Cost of Revenue | US$1.69b |
| Gross Profit | US$2.76b |
| Other Expenses | US$1.66b |
| Earnings | US$1.10b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.88 |
| Gross Margin | 62.05% |
| Net Profit Margin | 24.63% |
| Debt/Equity Ratio | 63.0% |
How did IDXX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 08:14 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDEXX Laboratories, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Michael Ryskin | BofA Global Research |